Mirae Asset Global Investments Co. Ltd. Has $324,000 Stake in bluebird bio, Inc. (NASDAQ:BLUE)

Mirae Asset Global Investments Co. Ltd. trimmed its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 58.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 234,972 shares of the biotechnology company’s stock after selling 335,960 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.21% of bluebird bio worth $324,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Aigen Investment Management LP acquired a new position in bluebird bio in the third quarter valued at about $34,000. Johnson Investment Counsel Inc. acquired a new position in bluebird bio in the third quarter valued at about $40,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in bluebird bio by 6.5% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 77,996 shares of the biotechnology company’s stock valued at $237,000 after acquiring an additional 4,751 shares during the period. New York State Common Retirement Fund grew its stake in bluebird bio by 17.0% in the third quarter. New York State Common Retirement Fund now owns 114,195 shares of the biotechnology company’s stock valued at $347,000 after acquiring an additional 16,603 shares during the period. Finally, Caxton Associates LP boosted its position in shares of bluebird bio by 187.9% during the third quarter. Caxton Associates LP now owns 152,389 shares of the biotechnology company’s stock worth $463,000 after buying an additional 99,464 shares during the period. 87.43% of the stock is owned by institutional investors and hedge funds.

bluebird bio Stock Up 1.1 %

NASDAQ:BLUE opened at $0.92 on Friday. The stock’s 50 day moving average price is $1.26 and its two-hundred day moving average price is $1.97. The firm has a market capitalization of $100.90 million, a price-to-earnings ratio of -1.25 and a beta of 0.74. bluebird bio, Inc. has a 12-month low of $0.88 and a 12-month high of $5.53.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on BLUE shares. William Blair reaffirmed a “market perform” rating on shares of bluebird bio in a research report on Tuesday, January 9th. StockNews.com raised bluebird bio to a “sell” rating in a research report on Thursday, March 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $6.00 price objective on shares of bluebird bio in a research report on Wednesday, March 27th. Wedbush reduced their price objective on bluebird bio from $1.72 to $1.68 and set a “neutral” rating for the company in a research report on Tuesday, March 19th. Finally, Wells Fargo & Company reduced their price objective on bluebird bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a research report on Wednesday, March 27th. Two analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.87.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.